A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04153929 on ClinicalTrials.gov · last registry update 2022-11-29
An unusually large phase 2: 413 participants, more than double the 110 typical for the stage. The sponsor logged completion for 8 October 2021. Primary outcome, as filed: Absolute Change in HbA1c From Baseline to 16 Weeks. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 413
- Started
- 2020-04-30
- Primary completion
- 2021-10-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Absolute Change in HbA1c From Baseline to 16 Weeks
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.